Perinatal EvidenceCompass
Prepopulated workbenchMED-243

Substance-use disorder — cannabis

Dronabinol

FDA-approved cannabinoid for nonpsychiatric indications; investigational/off-label for cannabis use disorder

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Dronabinol
Entity type
single-ingredient drug
Active component(s)
Dronabinol
Formulation / route / interval
Oral; formulation varies
Attachment entry
Dronabinol
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

2 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-027Provisional public source

No medication is FDA-approved for cannabis-use disorder, and nonpregnant candidate-drug studies do not justify replacing cannabis with NAC, prescription cannabinoids, nabiximols, or prescription CBD during pregnancy.

Public-source certainty descriptor
Moderate consensus; very low pregnancy drug evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy
Comparator
Candidate medication versus psychosocial CUD care
Effect or numbers carried forward

No established pregnancy efficacy

Limitations

Products differ in standardization and indication; CUD trials excluded pregnancy

Sources, citation controls, and verification state

Linked sources

PMID
40966737
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-029Provisional public source

Dronabinol, nabilone, nabiximols and Epidiolex are distinct standardized cannabinoid products; none should be treated as evidence that consumer cannabis or CBD is safe or effective in pregnancy.

Public-source certainty descriptor
High product-identity certainty; low reproductive evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
Prescription/authorized products versus consumer THC/CBD
Effect or numbers carried forward

Not applicable

Limitations

Each product has different THC/CBD content, route, label and jurisdiction

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending